Skip to main content

ICRF 159 and Other Bisdioxopiperazines

  • Chapter
Chemotherapy

Abstract

ICRF 159 ( (±)1,2-bis(.3, 5-dioxopiperazin-l-yl)propane) and a number of other bisdioxopiperazines are potent aptimetastatic compounds which inhibit the development of metastases from primary implants of the syngeneic Lewis lung carcinoma (3LL) in C57 BL mice (Hellmann & Burrage 1969; Salsbury, Burrage and Hellmann 1970). This effect is produced without evident influence on the growth rate of the primary tumour and thereby shows that it is possible to delete selectively one malignant characteristic of a tumour without influencing another. While this antimetastatic effect is not apparently unique amongst anticancer agents it seems to be the exception.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hellmann, K. & Burrage, Karen. Nature 224 273–275 (1969).

    Article  PubMed  CAS  Google Scholar 

  2. Salsbury, A.J., Burrage, Karen and Hellmann, K. (1970) British Medical Journal, 4, 344–346.

    Article  PubMed  CAS  Google Scholar 

  3. Creighton, A.N., Hellmann, K. & Whitecross, Susan (1969) Nature, 222, 384–385.

    Article  PubMed  CAS  Google Scholar 

  4. Salsbury, A.J., Burrage, Karen, & Hellmann, K. (1974). Cancer Research, 34, 843–849.

    PubMed  CAS  Google Scholar 

  5. James, Sandra E. & Salsbury, A.J. (1974) Cancer Research, 34, 839–842.

    PubMed  CAS  Google Scholar 

  6. Creighton, A.M. & Birnie, G.D. (1970) International Journal of Cancer, 5, 47–54.

    Article  CAS  Google Scholar 

  7. Hellmann, K. & Field, E.O. (1970) J. Nat. Cancer Inst. 44, 539–543.

    PubMed  CAS  Google Scholar 

  8. Sharpe, Heather B.A., Field, E.O. & Hellmann, K. (1970) Nature, 226, 524–526.

    Article  PubMed  CAS  Google Scholar 

  9. Hallowes, R.C., West, D.G. & Hellmann, K. (1974) Nature, 247 487–490.

    Article  PubMed  CAS  Google Scholar 

  10. Goldin, A., Venditti, J. & Mantel, N. (1975). in Antineoplastic and immunosuppressive agents Vol 1. Eds. A.C. Sartorelli & D.G. Johns, Springer, New York.

    Google Scholar 

  11. Wampler, G.L. (1973). Minutes of ICRF 159 meeting, National Cancer Institute, Bethesda, U.S.A. Ed. Wasserman, T.H.

    Google Scholar 

  12. Woodman, R.J., Kline, I. & Venditti, J.M. (1972). Proc. Amer. Ass. Cancer Res. 13, 31.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1976 Plenum Press, New York

About this chapter

Cite this chapter

Hellmann, K. (1976). ICRF 159 and Other Bisdioxopiperazines. In: Hellmann, K., Connors, T.A. (eds) Chemotherapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-4349-3_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-4349-3_17

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4351-6

  • Online ISBN: 978-1-4613-4349-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics